EBS FY 2012 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$422M

FY 2012 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$282M+3.1% YoY

Gross Profit

$113M39.9% margin

Operating Income

$37M13.0% margin

Net Income

$24M8.3% margin

EPS (Diluted)

$0.65

Cash Flow

Operating Cash Flow

$40M

Free Cash Flow

-$14M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$564M

Total Liabilities

$122M

Stockholders' Equity

$441M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$282M	$273M	+3.1%
Gross Profit	$113M	$231M	-51.3%
Operating Income	$37M	$32M	+13.9%
Net Income	$24M	$23M	+2.2%